Deep Learning for Analysis of Bone Marrow Adiposity: Breakthroughs from Recent Large-Scale Analyses in the UK Biobank.
Authors
Affiliations (5)
Affiliations (5)
- Centre for Global Health, Usher Institute, University of Edinburgh, EH8 9AG, Edinburgh, UK.
- Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh BioQuarter, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK.
- Edinburgh Imaging, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh BioQuarter, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK.
- School of Mathematics and Computer Sciences, Heriot-Watt University, Edinburgh, EH14 1AS, UK.
- Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh BioQuarter, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK. [email protected].
Abstract
Bone marrow adipose tissue (BMAT) is a significant fat depot with distinct skeletal, haematological and metabolic roles. It increases with ageing, osteoporosis, metabolic disease, and cancer, and is emerging as a biomarker for fracture risk. Quantification of bone marrow adiposity (BMA) has relied on MRI, proton spectroscopy, computed tomography, or histology, but large-scale studies have been limited by requiring labour-intensive analysis. Deep learning (DL) now enables scalable, automated BMA measurement, with greatest progress in MRI. This review highlights recent advances. DL models, especially U-Nets, have been applied to UK Biobank MRI data, allowing site-specific BM fat fraction (BMFF) measurement or calvarial BMA estimation in tens of thousands of participants. These breakthroughs have revealed robust associations between BMA and age, sex, ethnicity, bone mineral density, adiposity, and metabolic traits, while uncovering site-specific patterns. Genome-wide association studies of BMFF and calvarial BMA have defined their genetic architecture, identifying hundreds of loci enriched for pathways in oestrogen signalling, adipogenesis, and skeletal remodelling. Phenome-wide association studies demonstrate links between altered BMFF and osteoporosis, fracture, type 2 diabetes, cardiovascular disease, and diverse other conditions, with Mendelian randomisation providing the first causal evidence that increased femoral BMFF contributes to osteoporosis. Despite successes, challenges remain, including extending analyses to non-European ancestries and validating DL pipelines in clinical settings. Collectively, DL-enabled BMA quantification has established BMAT as a clinically relevant, genetically tractable fat depot and provides new opportunities for mechanistic insight, risk prediction, and therapeutic targeting in musculoskeletal, metabolic, and other diseases.